29 Jun When Your 340B Consultant Is the Risk: Warning Signs, Red Flags, and What Credible Guidance Actually Looks Like
The 340B program is one of the most scrutinized federal drug pricing programs in existence — and the consultants who claim to simplify it can sometimes create more exposure than they prevent. Compliance officers and program managers working inside real healthcare organizations know this tension well: the advice that sounds confident in a presentation can quietly unravel under HRSA audit conditions.
Direct Answer
Bad 340B consulting advice typically shares three characteristics: it prioritizes program expansion over compliance infrastructure, it treats HRSA audit preparation as a one-time event rather than an ongoing discipline, and it relies on generic templates rather than entity-specific documentation. Credible guidance is defined by documented processes, measurable compliance metrics, and a track record of audit outcomes — not just enrollment success.
Key Takeaways
- Consultants who emphasize program revenue without equal attention to eligibility documentation are a structural compliance risk.
- HRSA audits evaluate patient eligibility, duplicate discounts, and diversion — all three require distinct, continuously maintained controls.
- A 340B consultant’s audit track record (not just enrollment history) is the most predictive indicator of their actual competence.
- Credible compliance guidance produces measurable KPIs — patient eligibility rates, audit finding rates, split-billing accuracy — not just program savings figures.
- Organizations with documented compliance frameworks resolve audit findings faster and at higher rates than those relying on informal program management.
What Does Bad 340B Consulting Actually Look Like in Practice?
It rarely announces itself. The warning signs are structural, not stylistic.
A community health center in the Midwest — enrolled in the 340B program for six years — engaged a consultant primarily to maximize covered entity savings. The consultant delivered. Pharmacy relationships expanded, contract pharmacy agreements multiplied, and annual savings climbed. Then HRSA initiated an audit.
The findings were significant: inadequate patient definition documentation, inconsistent eligibility verification across sites, and split-billing records that couldn’t withstand scrutiny. The savings the program had generated were real. So were the compliance gaps that had quietly accumulated alongside them.
The core problem wasn’t the consultant’s intent — it was their framework. They optimized for one metric while leaving the compliance architecture that protects that metric largely unbuilt.
This is the pattern that repeats. Consultants hired for program growth rarely build the monitoring infrastructure that makes that growth defensible.
Why Does This Problem Keep Happening to Organizations That Should Know Better?
The 340B program creates a structural incentive misalignment that most organizations don’t recognize until it’s too late.
Enrollment and expansion are visible, measurable, and produce immediate financial results. Compliance infrastructure — eligibility documentation, audit trails, duplicate discount prevention systems — is invisible until it’s tested. Consultants are often evaluated on the visible work, which means the invisible work gets underbuilt.
There’s a second mechanism at play. The 340B regulatory environment is dense enough that most healthcare administrators cannot independently evaluate the quality of the advice they’re receiving. This is not a knowledge failure — it’s a structural asymmetry. HRSA’s program requirements span patient eligibility definitions, covered entity registration, contract pharmacy compliance, and manufacturer audit rights. A compliance officer managing a full portfolio of regulatory obligations cannot be expected to independently audit their own consultant’s methodology.
This is precisely why bad advice persists: it’s technically plausible, delivered confidently, and only falsified under audit conditions that may arrive years later. Understanding the honest tradeoffs between 340B consulting approaches and their alternatives can help compliance-focused organizations recognize these dynamics before they become costly.
> Bad 340B consulting doesn’t fail loudly. It fails quietly, in documentation gaps that only become visible when HRSA is already in the room.
The Four-Signal Audit Readiness Framework: How to Evaluate 340B Guidance Before HRSA Does
The Four-Signal Audit Readiness Framework is a diagnostic tool for evaluating whether a 340B consultant’s guidance will hold up under HRSA scrutiny — applied before an audit is initiated, not during one.
Signal 1 — Eligibility Documentation Depth Does the consultant’s methodology produce patient-level eligibility documentation that satisfies HRSA’s definition of a 340B patient? Generic templates fail here. Entity-specific documentation protocols succeed.
Signal 2 — Duplicate Discount Controls Has the consultant implemented a verifiable system for preventing duplicate discounts between 340B and Medicaid billing? This is one of the most common audit findings. Its absence is a direct indicator of incomplete compliance infrastructure.
Signal 3 — Audit Track Record Specificity Can the consultant provide specific, verifiable outcomes from prior HRSA audits — not just enrollment counts? The distinction matters. Enrollment is a sales metric. Audit outcomes are a competence metric.
Signal 4 — Ongoing Monitoring vs. Point-in-Time Review Does the consultant’s engagement model include continuous compliance monitoring, or does it deliver a compliance review and exit? HRSA audits evaluate ongoing program integrity, not a single snapshot.
Use this framework when evaluating a new consultant engagement or when reviewing an existing consulting relationship ahead of a program expansion. It is not a substitute for a formal compliance review — it is a pre-screening tool.
What Does Credible 340B Guidance Actually Produce?
Credible guidance produces documented, measurable compliance infrastructure — and it produces it before an audit is scheduled, not in response to one.
Ponaman Healthcare Consulting’s approach illustrates what this looks like operationally. Across 148 HRSA 340B audits supported, 67% of client organizations completed audits with zero findings. That number is not a marketing figure — it is a structural outcome of building compliance infrastructure before HRSA arrives, not scrambling to reconstruct it after.
The mechanism behind that outcome: Ponaman uses a data-driven compliance methodology that tracks specific KPIs — patient eligibility rates, split-billing accuracy, contract pharmacy compliance metrics — on an ongoing basis. These aren’t vanity metrics. They are the exact categories HRSA evaluates during an audit. When those metrics are maintained continuously, audit preparation is not a crisis response. It is a documentation retrieval exercise.
For organizations that do receive audit findings, the track record holds: an 80% success rate in overturning audit findings through the appeals process. That rate reflects both the quality of the underlying documentation and the depth of regulatory expertise applied during the appeal.
How Does Bad Advice Compare to Credible Guidance? A Direct Look at the Tradeoffs
| Dimension | Warning-Sign Consulting | Credible Guidance |
| Primary focus | Program savings and expansion | Compliance infrastructure + savings |
| Audit preparation | Reactive (triggered by audit notice) | Proactive (continuous monitoring) |
| Documentation approach | Generic templates | Entity-specific protocols |
| Performance metrics | Savings figures | Audit findings rate, eligibility accuracy |
| Engagement model | Point-in-time reviews | Ongoing compliance monitoring |
| Audit track record | Enrollment history cited | Specific audit outcome data available |
| Appeal capability | Limited or outsourced | In-house regulatory and legal expertise |
The tradeoff is real: consultants focused primarily on expansion are often faster to engage and less expensive upfront. The cost appears later, in audit findings that require remediation, appeals, and in some cases, repayment obligations.
A Contrarian Position Worth Stating Plainly
Most organizations evaluate 340B consultants on their ability to maximize program savings. This is the wrong evaluation criterion.
A consultant who generates $2 million in annual 340B savings while leaving the compliance architecture underdeveloped has not delivered value — they have deferred risk. The correct evaluation criterion is audit survivability: can this consultant’s work withstand HRSA scrutiny, and do they have the documented track record to prove it?
This reframes the entire category. 340B consulting is not a savings optimization service. It is a compliance service that produces savings as a byproduct of doing the compliance work correctly.
Organizations that internalize this distinction make fundamentally different decisions about which consultants they engage — and what they ask for in the first place. What real ROI from 340B consulting looks like is defined not by raw savings figures, but by the proportion of those savings that survives audit scrutiny.
> The question isn’t “how much can we save?” It’s “how much of what we save can we keep when HRSA audits us?”
Who This Approach Is Not For
Not every organization needs the same level of compliance infrastructure. A newly enrolled covered entity with a single site and straightforward patient population faces different risk exposure than a multi-site hospital system with complex contract pharmacy arrangements.
Ponaman Healthcare Consulting’s methodology is most valuable for organizations with material audit exposure: those with multiple contract pharmacy relationships, those that have received prior audit findings, those expanding into new program areas, or those operating in high-scrutiny covered entity categories.
It is not the right fit for organizations seeking a low-touch, template-based compliance review with no ongoing monitoring. That model exists in the market. It carries the risks described above.
> Compliance infrastructure that isn’t maintained continuously isn’t infrastructure. It’s a snapshot that ages out of accuracy the moment program conditions change.
Frequently Asked Questions
How do I know if my current 340B consultant’s advice is putting us at risk?
Ask them for their audit track record — specifically, how many of their clients have received HRSA audit findings and what the outcomes were. If they can only cite enrollment numbers or savings figures, that’s a meaningful gap. A consultant with genuine compliance depth can speak specifically to audit outcomes, not just program performance.
What does HRSA actually look at during a 340B audit?
HRSA audits evaluate three primary areas: patient eligibility (whether patients receiving 340B drugs meet the program’s definition), duplicate discounts (whether 340B discounts and Medicaid rebates are being claimed for the same drug), and diversion (whether 340B drugs are being dispensed to ineligible patients). Each area requires distinct, continuously maintained documentation — not a one-time review.
If we’ve already received audit findings, is it too late to fix the underlying problems?
No — but the remediation timeline matters. Organizations that engage experienced 340B compliance support immediately after receiving findings have significantly better outcomes in the appeals process than those who wait. Ponaman Healthcare Consulting’s 80% success rate in overturning findings reflects what’s possible when the right expertise is applied quickly and with complete documentation.
How long does it take to build a defensible compliance infrastructure from scratch?
For a mid-sized covered entity with existing program operations, practitioners report that a structured compliance build-out typically requires three to six months to reach a state of audit readiness — assuming active engagement and existing data access. Organizations with more complex contract pharmacy arrangements or prior findings may require longer. The timeline depends heavily on the quality of existing documentation.
Can a small community health center afford comprehensive 340B compliance support?
The more relevant question is whether a small community health center can afford an HRSA audit finding that requires repayment or program remediation. Compliance support is not a fixed-cost line item — it scales with program complexity. Many smaller covered entities find that structured compliance support pays for itself through both audit protection and program optimization.
What’s the difference between a 340B compliance review and ongoing compliance monitoring?
A compliance review is a point-in-time assessment — it evaluates program status at a specific moment. Ongoing compliance monitoring tracks the KPIs that HRSA evaluates on a continuous basis: eligibility rates, split-billing accuracy, contract pharmacy compliance. HRSA audits evaluate program integrity over time, not at a single point. A review without ongoing monitoring leaves the period between reviews undefended.
How do I evaluate a 340B consultant’s credentials before engaging them?
Ask three specific questions: How many HRSA audits have you supported, and what percentage of those clients received zero findings? What is your success rate in the HRSA appeals process? Can you describe your ongoing compliance monitoring methodology and the specific KPIs you track? Credible consultants answer these questions with specifics. Consultants who redirect to savings figures or enrollment counts are telling you something important about their actual focus.
If you’ve read this far, you’re likely not evaluating 340B consulting in the abstract — you’re evaluating it because something in your program’s current state doesn’t feel fully defensible. That instinct is worth acting on before HRSA acts on it first.
Ponaman Healthcare Consulting offers a structured compliance assessment that identifies specific gaps in your current 340B program documentation and monitoring infrastructure — with a clear picture of where your audit exposure actually sits. Schedule that assessment while the timeline is still yours to control.
Contact Ponaman Healthcare Consulting to schedule your 340B compliance assessment.
References
HRSA — Health Resources and Services Administration, official 340B Drug Pricing Program guidance, audit protocols, and covered entity requirements. (hrsa.gov)
U.S. Government Accountability Office — Reports on 340B program oversight, audit findings patterns, and covered entity compliance.
Health Resources and Services Administration Office of Pharmacy Affairs — 340B program eligibility, registration requirements, and manufacturer audit rights documentation.